A total of 33,376 patents were granted across medical industry between July 2021 and September 2021, marking a 2% jump over the previous quarter (April 2021-June 2021), according to GlobalData Patents Database.
Patenting activity by top assignee
Go deeper with GlobalData
Out of 4,317 active assignees during the review quarter, Boston Scientific registered a growth change of 23% with 231 patent grants, followed by Medtronic with 18% (588), Becton Dickinson and Co with 2% (290), Koninklijke Philips with -2% (390) and Johnson & Johnson with -11% (760).
| Filings | Grants |
General Surgery was the most active technology application with 952 patent grants, followed by Diagnostic Imaging with 250 and Cardiovascular Devices with 218.
The least active IP protected technology applications include Pacemakers and Bipolar Electrodes with 10 and five patent grants, respectively.
Assignee highest and lowest growth rate
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataLutronic; Sekisui Chemical; and Tufts University saw the leading growth rates of 700%; 600%; and 600%, respectively in patent grants during Jul-Sep 2021 compared with the previous three-month period, while Milux Holding saw the lowest growth rate of -92%.
Patenting activity: Leading themes in the Jul-Sep 2021 quarter
Artificial Intelligence led the medical sector with 1,006 patents during the review quarter, followed by Wearable Tech and Smart Hospitals with 563 and 512 patents, respectively.
Patenting activity: Sub sector composition
In terms of sub-sector composition, General Surgery led IP protection with 4,650 patent grants during the review quarter, followed by Diagnostic Imaging with 2,147, Anesthesia and Respiratory Devices with 2,061, Orthopedic Devices with 1,734, and Other Remote Patient Monitoring with 1,433.
IP protection activity by region
China led IP protection activity with 6,156 grants and 2,630 new filings during the Jul-Sep 2021 quarter, followed by the US with 3,580 grants and 4,086 new filings.
Japan came in next with 544 grants and 1,086 new filings. Korea (South) and Australia stood next with 742 grants and 687 new filings; 196 grants and 321 new filings, respectively.
New entrants in Jul-Sep 2021
Xenter, Sorcero, DeTect, eXithera Pharmaceuticals and Makani Science are the five new entrants in the Medical industry with eight, five, five, three and three patent filings, respectively during the Jul-Sep 2021 quarter.
Methodology:
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus. Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
For generation of above insights, we have considered the 63,911 documents published during the period of July 2021 to September 2021. This data was tagged to 17 themes, 326 sectors, 5,287 assignees, 120,825 inventors and 51 countries.
Additional details on above insights are available on GlobalData’s suite of platforms or contact us directly for further engagement.
Disclaimer: All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData. The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GlobalData delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, GlobalData can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect.
